Codelivery of Doxorubicin and shAkt1 by Poly(ethylenimine)-Glycyrrhetinic Acid Nanoparticles To Induce Autophagy-Mediated Liver Cancer Combination Therapy

Mol Pharm. 2016 Apr 4;13(4):1298-307. doi: 10.1021/acs.molpharmaceut.5b00879. Epub 2016 Mar 16.

Abstract

Combination therapy has been developed as a promising therapeutic approach for hepatocellular carcinoma therapy. Here we report a low toxicity and high performance nanoparticle system that was self-assembled from a poly(ethylenimine)-glycyrrhetinic acid (PEI-GA) amphiphilic copolymer as a versatile gene/drug dual delivery nanoplatform. PEI-GA was synthesized by chemical conjugation of hydrophobic GA moieties to the hydrophilic PEI backbone via an acylation reaction. The PEI-GA nanocarrier could encapsulate doxorubicin (DOX) efficiently with loading level about 12% and further condense DNA to form PEI-GA/DOX/DNA complexes to codeliver drug and gene. The diameter of the complexes is 102 ± 19 nm with zeta potential of 19.6 ± 0.2 mV. Furthermore, the complexes possess liver cancer targeting ability and could promote liver cancer HepG2 cell internalization. Apoptosis of cells could be induced by chemotherapy of DOX, and PI3K/Akt/mTOR signaling pathway acts a beneficial effect on the modulation of autophagy. Here, it is revealed that utilizing PEI-GA/DOX/shAkt1 complexes results in effective autophagy and apoptosis, which are useful to cause cell death. The induction of superfluous autophagy is reported to induce type-II cell death and also could increase the sensity of chemotherapy to tumor cells. In this case, combining autophagy and apoptosis is meaningful for oncotherapy. In this study, PEI-GA/DOX/shAkt1 has demonstrated favorable tumor target ability, little side effects, and ideal antitumor efficacy.

Keywords: autophagy; combination therapy; glycyrrhetinic acid; liver cancer targeting; self-assembled.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autophagy / drug effects*
  • Doxorubicin / administration & dosage*
  • Doxorubicin / chemistry*
  • Doxorubicin / therapeutic use
  • Glycyrrhetinic Acid / chemistry*
  • Hep G2 Cells
  • Humans
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / metabolism
  • Male
  • Mice
  • Nanoparticles / chemistry*
  • Nanoparticles / therapeutic use
  • Polyethyleneimine / chemistry*
  • Polymers / chemistry
  • Polymers / pharmacology*
  • Polymers / therapeutic use
  • Proto-Oncogene Proteins c-akt / genetics
  • RNA, Small Interfering / administration & dosage*
  • RNA, Small Interfering / chemistry*

Substances

  • Polymers
  • RNA, Small Interfering
  • Doxorubicin
  • Polyethyleneimine
  • Proto-Oncogene Proteins c-akt
  • Glycyrrhetinic Acid